Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology
Shinozuka K, Jerotic K, Mediano P, Zhao A, Preller K, Carhart-Harris R, Kringelbach M. Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology. Translational Psychiatry 2024, 14: 485. PMID: 39632810, PMCID: PMC11618481, DOI: 10.1038/s41398-024-03187-1.Peer-Reviewed Original ResearchConceptsFunctional connectivityBetween-network functional connectivityLevels of analysisWithin-network FCBetween-drug differencesMeta-analysesD2 receptorsPsychedelic effectsSerotonergic psychedelicsNeuroimaging resultsNeuropsychiatric disordersStates of consciousnessPsychedelicsNeural fingerprintsAltered statesNeuroimagingPsilocybinHigh dosesLSDSignificantly higher ratesMolecular pharmacologySystematic reviewAddictionDepressionPhenomenologyNeuroimaging Biomarkers for Drug Discovery and Development in Schizophrenia
Preller K, Scholpp J, Wunder A, Rosenbrock H. Neuroimaging Biomarkers for Drug Discovery and Development in Schizophrenia. Biological Psychiatry 2024, 96: 666-673. PMID: 38272287, DOI: 10.1016/j.biopsych.2024.01.009.Peer-Reviewed Original ResearchNMDA receptor hypofunctionPsychosis spectrum disordersNeuroimaging data acquisitionField of neuroimagingNegative symptomsPharmacological neuroimagingPositive symptomsReceptor hypofunctionPsychotic disordersNeuroimaging resultsSpectrum disorderNeuroimaging technologiesNeuroimaging biomarkersSchizophreniaNeuroimagingPathophysiology of symptomsDrug developmentDecades of researchTarget engagementClinical drug developmentPredictive biomarkersDisordersSymptomsHealthy volunteersDose selection